Childhood obesity is one of the most serious public health problems with obesity-related complications such as hepatosteatosis or type 2 diabetes occurring during early childhood. The aim of this study was to examine the relationship between 25-hydroxy vitamin D levels and obesity with hepatosteatosis (HS) in children. 128 obese children participated in this study. Hepatosteatosis was diagnosed and graded using ultrasonography in all patients. Serum levels of 25-hydroxy vitamin D, calcium, phosphate, alkaline phosphatase (ALP), parathormone (PTH), lipid, glucose and insulin were also measured. The data was analyzed across two groups of obese children those with hepatosteatosis and those without hepatosteatosis. Forty-two percent of the study group were male. The mean age of the subjects was 12.1±3.1 years (range 4-18 years). Hepatosteatosis was identified in 39% of children (n: 50). A high prevalence (122/128 cases, 95%) of either 25-hydroxy vitamin D deficiency or insufficiency was determined. However, there was no statistically significant association between 25-hydroxy vitamin D levels and hepatosteatosis. Uric acid, alanine aminotransferase (ALT) and triglyceride levels were significantly higher in the HS group compared to non-HS group. There is a high prevalence of 25-hydroxy vitamin D deficiency and insufficiency among children with hepatosteatosis. However, in this study, no association was observed between 25-hydroxy vitamin D deficiency and hepatosteatosis.
Key words: Childhood, Obesity, Hepatosteatosis, 25 hydroxy vitamin D
|
